Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.1 USD | +3.68% | -4.02% | -3.73% |
08/03 | Ovid Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
08/03 | Earnings Flash (OVID) OVID THERAPEUTICS Reports Q4 Revenue $141,562 | MT |
Business Summary
Number of employees: 40
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Novel Therapeutics
100.0
%
| 2 | 100.0 % | 0 | 100.0 % | -73.93% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 2 | 100.0 % | 0 | 100.0 % | -73.93% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Jeremy Levin
CEO | Chief Executive Officer | 70 | 01/14/01 |
Jeffrey Rona
DFI | Director of Finance/CFO | 55 | 01/19/01 |
Zhong Zhong
CTO | Chief Tech/Sci/R&D Officer | - | 28/23/28 |
Manoj Malhotra
CTO | Chief Tech/Sci/R&D Officer | - | 08/23/08 |
Jason Tardio
COO | Chief Operating Officer | 47 | 18/19/18 |
Julia Tsai
CTO | Chief Tech/Sci/R&D Officer | - | 08/21/08 |
Thomas Perone
CMP | Compliance Officer | 59 | 21/19/21 |
Toshiya Nishi
PRN | Corporate Officer/Principal | - | 08/23/08 |
Megan Alexander
PRN | Corporate Officer/Principal | - | - |
Corporate Officer/Principal | - | 01/15/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Barbara Duncan
BRD | Director/Board Member | 59 | 14/17/14 |
Bart Friedman
BRD | Director/Board Member | 79 | 23/15/23 |
Jeremy Levin
CEO | Chief Executive Officer | 70 | 01/14/01 |
Karen Bernstein
BRD | Director/Board Member | 71 | 30/15/30 |
Robert Poole
BRD | Director/Board Member | 67 | 09/21/09 |
Kevin Fitzgerald
BRD | Director/Board Member | 56 | 06/21/06 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 70,810,661 | 59,503,870 ( 84.03 %) | 0 | 84.03 % |
Stock B | 0 | 1,250 | 0 | 0 |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.73% | 220M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- OVID Stock
- Company Ovid Therapeutics Inc.